Wall Street is positive on Arcturus Therapeutics Holdings Inc (ARCT). On average, analysts give the stock a Buy rating. The average price target is $44.25, which means analysts expect the stock to add by 68.44% over the next twelve months. That average ranking earns the stock an Analyst Rating of 33, which is better than 33% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating ARCT a Buy today. Find out what this means to you and get the rest of the rankings on ARCT!